SCHEMBL31085015

SCHEMBL31085015

CC(=O)CC(=O)c1ccc(Br)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
GAA P10253 2/20 0.49
LMNA P02545 2/20 0.49
ALOX12 P18054 1/20 0.49
POLB P06746 1/20 0.45
HSP90AB1 P08238 1/20 0.44
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
HPGD P15428 2/20 0.44
CES2 O00748 1/20 0.44
GALR3 O60755 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CYP2C19 P33261 1/20 0.44
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591498 1.00 MAPT (0.49) MAPTNPC1RAB9AGAALMNA
SCHEMBL24763383 0.83 HSP90AB1 (0.50) MAPTNPC1RAB9AGAALMNA
SCHEMBL7534898 0.81 HSP90AB1 (0.67) MAPTNPC1RAB9AGAALMNA
SCHEMBL30863507 0.81 HSP90AB1 (0.67) MAPTNPC1RAB9AGAALMNA
SCHEMBL25666683 0.81 MAPT (0.54) MAPTNPC1RAB9AGAALMNA
SCHEMBL17506959 0.81 DGAT1 (0.56) MAPTNPC1RAB9AGAALMNA
SCHEMBL31320843 0.80 RAB9A (0.70) MAPTNPC1RAB9ALMNAPOLB
SCHEMBL8464964 0.80 RAB9A (0.70) MAPTNPC1RAB9ALMNAPOLB
SCHEMBL24939658 0.79 MAPT (0.53) MAPTNPC1RAB9AGAALMNA
SCHEMBL3527659 0.79 CA12 (0.46) MAPTNPC1RAB9AGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
WO-2024160277-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2024-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 MAPT 3357/4885NPC1 978/4885RAB9A 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.